Group 1 - Takeda is currently facing significant valuation issues, particularly after the costly acquisition of Shire [1] - The company has implemented effective kaizen practices to improve its pipeline [1] - Takeda presents a unique biopharma case that may lead to investment opportunities despite its challenges [1]